Welcome to our dedicated page for ASTRAZENECA PLC SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASTRAZENECA PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASTRAZENECA PLC's regulatory disclosures and financial reporting.
AstraZeneca PLC reported a Director/PDMR shareholding update. The company was notified that Chief Financial Officer Aradhana Sarin executed a sale of 15,000 American Depositary Shares (ADSs) at $88.6345 per ADS. The transaction occurred on 12 November 2025 and was conducted on XNAS.
Two ADSs are equivalent to one ordinary share of $0.25 each. The notification was made in accordance with the EU Market Abuse Regulation as it forms part of UK law.
AstraZeneca PLC reported a Director/PDMR shareholding update. On 7 November 2025, CEO Pascal Soriot gifted 136,537 ordinary shares of $0.25 each in AstraZeneca PLC to family members for nil consideration, and therefore ceased to be beneficially interested in those shares.
The transaction was conducted outside a trading venue and is disclosed as a gift under EU Market Abuse Regulation requirements as retained in UK law.
AstraZeneca PLC reported strong 9M and Q3 2025 results, highlighting broad-based growth and pipeline momentum. Total Revenue reached $43,236m for 9M (up 11% at CER), with Q3 at $15,191m (up 10% at CER). Reported EPS was $5.10 for 9M (up 42%) and $1.64 in Q3 (up 70%), while Core EPS rose to $7.04 for 9M (up 15%) and $2.38 in Q3 (up 12% at CER).
Growth was driven by all therapy areas, notably Oncology (9M up 16% at CER) and R&I (up 13%), with Alliance Revenue up 41%. Q3 Gross Margin was 82% and Core Operating Profit increased, reflecting operating leverage despite higher R&D to support late‑stage programs. Management reiterated FY 2025 guidance: Total Revenue to increase by a high single-digit percentage and Core EPS by a low double-digit percentage, with a Core tax rate of 18–22%.
The company cited “unprecedented” pipeline delivery with 16 positive Phase III readouts year‑to‑date and 31 approvals across major regions. Strategic initiatives included progress on listing harmonisation targeting February 2, 2026 and US manufacturing expansion, breaking ground on a $4.5bn Virginia facility as part of plans to invest $50bn in US manufacturing and R&D by 2030.
AstraZeneca PLC reported that shareholders approved a special resolution to adopt new articles of association to proceed with the harmonisation of its equity listing structure. The motion passed by poll with 1,222,275,967 votes for (99.36% of votes cast) and 7,861,875 against (0.64%), from 1,230,137,842 votes cast in total (79.33% of issued share capital); 2,628,613 votes were withheld.
The timetable replicates prior guidance: termination of the ADR programme, delisting of AstraZeneca ADSs, and cancellation of the listing and trading of AstraZeneca US Bonds on Nasdaq is expected on 2 February 2026. Trading in AstraZeneca Shares and AstraZeneca US Bonds on the NYSE is expected to commence by 8:00 a.m. (ET) on 2 February 2026. Issuance of AstraZeneca DIs to relevant CREST participant accounts is expected on or around 2 February 2026, and statements of entitlement for existing CSN Eligible Certificated Shareholders and CSN Participants by no later than 16 February 2026.
Issued shares were 1,550,712,906 ordinary shares as of 30 October 2025.
AstraZeneca PLC reported its total voting rights under the UK Disclosure and Transparency Rule 5.6.1. As at 31 October 2025, the company’s issued share capital with voting rights comprised 1,550,712,906 ordinary shares of US$0.25. No shares are held in Treasury, so the total number of voting rights is 1,550,712,906.
This figure serves as the denominator shareholders use to assess whether they must notify their interest or any change in interest in line with UK transparency rules. The company files annual reports on Form 20-F and indicated it is not furnishing information under Rule 12g3-2(b).
AstraZeneca PLC furnished a Form 6-K announcing an update to its corporate governance documents. Exhibit 99.1 contains the company’s Articles of Association, adopted by special resolution passed on 3 November 2025. The filing indicates AstraZeneca files annual reports on Form 20-F and is not furnishing information under Rule 12g3-2(b).
AstraZeneca PLC announced that Non-Executive Director Euan Ashley has been appointed a director of DexCom, Inc., effective 24 October 2025.
This routine governance disclosure was made pursuant to Listing Rule 6.4.9 (2). The notice was signed by Company Secretary Matthew Bowden on 28 October 2025.
AstraZeneca announced that the European Commission approved Koselugo (selumetinib) for adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on the Phase III KOMET trial, which showed a 20% objective response rate in tumour size reduction versus 5% with placebo (p=0.01) by cycle 16.
Investigators reported a safety profile consistent with prior paediatric use. After 12 treatment cycles, placebo patients crossed over to Koselugo, and those on Koselugo continued for another 12 cycles. The medicine has recent approvals in Japan and other countries for this adult population, with additional reviews ongoing.
AstraZeneca PLC announced that the European Commission approved Tezspire (tezepelumab) as an add-on with intranasal corticosteroids for adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard therapy. The decision is based on the Phase III WAYPOINT trial, where Tezspire reduced nasal polyp severity, nearly eliminated the need for surgery, and significantly reduced systemic corticosteroid use versus placebo.
The safety and tolerability profile was generally consistent with prior experience; the most frequent adverse events were COVID-19, nasopharyngitis and upper respiratory tract infection. CRSwNP affects approximately 320 million people worldwide, and nearly half of European patients remain uncontrolled despite current treatments. Tezspire is already approved for severe asthma in the US, EU, Japan and more than 60 countries, and was recently approved in the US for inadequately controlled CRSwNP in patients aged 12 and older.
Under AstraZeneca’s collaboration with Amgen, costs and profits are shared equally; Amgen records US product sales with AstraZeneca recognizing its US profit share as Collaboration Revenue, while AstraZeneca records product sales outside the US.
AstraZeneca (AZN) announced US FDA approval of Tezspire (tezepelumab) for chronic rhinosinusitis with nasal polyps (CRSwNP) as an add‑on maintenance treatment for adults and adolescents aged 12 years and older with inadequately controlled disease. This expands Tezspire beyond severe asthma into a second epithelial‑driven inflammatory condition, targeting thymic stromal lymphopoietin (TSLP).
The decision was supported by the Phase III WAYPOINT trial, where Tezspire delivered a statistically significant, clinically meaningful reduction in nasal polyp severity, with near‑elimination of surgery and significant reductions in systemic corticosteroid use versus placebo. CRSwNP affects up to approximately 320 million people worldwide, and many patients do not achieve lasting relief with current therapies. AstraZeneca and Amgen co‑develop and co‑commercialize Tezspire, sharing costs and profits; in the US, Amgen records product sales with AstraZeneca recognizing its share as Collaboration Revenue. A positive CHMP opinion has been adopted in the EU, and reviews are ongoing in multiple countries.